de Leij LF - Search Results

1

Trzpis M, Bremer E, McLaughlin PM, de Leij LF, Harmsen MC. Trzpis M, et al. Among authors: de leij lf. Front Biosci. 2008 May 1;13:5050-5. doi: 10.2741/3063. Front Biosci. 2008. PMID: 18508569 Review.

2

Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model.

Kosterink JG, McLaughlin PM, Lub-de Hooge MN, Hendrikse HH, van Zanten J, van Garderen E, Harmsen MC, de Leij LF. Kosterink JG, et al. Among authors: de leij lf. J Immunol. 2007 Jul 15;179(2):1362-8. doi: 10.4049/jimmunol.179.2.1362. J Immunol. 2007. PMID: 17617629

3

EpCAM in carcinogenesis: the good, the bad or the ugly.

van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. van der Gun BT, et al. Among authors: de leij lf. Carcinogenesis. 2010 Nov;31(11):1913-21. doi: 10.1093/carcin/bgq187. Epub 2010 Sep 13. Carcinogenesis. 2010. PMID: 20837599 Review.

4

Tumor-targeted immune complex formation: effects on myeloid cell activation and tumor-directed immune cell migration.

Kroesen BJ, McLaughlin PM, Schuilenga-Hut PH, Jacobs SC, Molema G, Helfrich W, De Leij LF. Kroesen BJ, et al. Among authors: de leij lf. Int J Cancer. 2002 Apr 20;98(6):857-63. doi: 10.1002/ijc.10245. Int J Cancer. 2002. PMID: 11948463 Free article.

5

Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines.

McLaughlin PM, Trzpis M, Kroesen BJ, Helfrich W, Terpstra P, Dokter WH, Ruiters MH, de Leij LF, Harmsen MC. McLaughlin PM, et al. Among authors: de leij lf. Cancer Gene Ther. 2004 Sep;11(9):603-12. doi: 10.1038/sj.cgt.7700725. Cancer Gene Ther. 2004. PMID: 15243630

6

Persistent downregulation of the pancarcinoma-associated epithelial cell adhesion molecule via active intranuclear methylation.

van der Gun BTF, Wasserkort R, Monami A, Jeltsch A, Raskó T, Ślaska-Kiss K, Cortese R, Rots MG, de Leij LFMH, Ruiters MHJ, Kiss A, Weinhold E, McLaughlin PMJ. van der Gun BTF, et al. Among authors: de leij lfmh. Int J Cancer. 2008 Jul 15;123(2):484-489. doi: 10.1002/ijc.23476. Int J Cancer. 2008. PMID: 18398839 Free article.

7

The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy.

McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, Hollema H, Ruiters MH, Buys CH, de Leij LF. McLaughlin PM, et al. Among authors: de leij lf. Cancer Res. 2001 May 15;61(10):4105-11. Cancer Res. 2001. PMID: 11358833

8

Cancer immunotherapy: insights from transgenic animal models.

McLaughlin PM, Kroesen BJ, Harmsen MC, de Leij LF. McLaughlin PM, et al. Among authors: de leij lf. Crit Rev Oncol Hematol. 2001 Oct;40(1):53-76. doi: 10.1016/s1040-8428(00)00129-3. Crit Rev Oncol Hematol. 2001. PMID: 11578916 Review.

9

Chemokine scavenging by the human cytomegalovirus chemokine decoy receptor US28 does not inhibit monocyte adherence to activated endothelium.

Boomker JM, de Jong EK, de Leij LF, Harmsen MC. Boomker JM, et al. Among authors: de jong ek, de leij lf. Antiviral Res. 2006 Feb;69(2):124-7. doi: 10.1016/j.antiviral.2005.11.003. Epub 2005 Dec 7. Antiviral Res. 2006. PMID: 16368154

10

The human cytomegalovirus-encoded receptor US28 increases the activity of the major immediate-early promoter/enhancer.

Boomker JM, The TH, de Leij LF, Harmsen MC. Boomker JM, et al. Among authors: de leij lf. Virus Res. 2006 Jun;118(1-2):196-200. doi: 10.1016/j.virusres.2005.12.011. Epub 2006 Jan 31. Virus Res. 2006. PMID: 16448715

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

186 results

Search Page